Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Anticipates Speeding Up R&D By Joining OECD As Observer - DIA China Conference

This article was originally published in PharmAsia News

Executive Summary

BEIJING - China's status as an observer country in the Organization for Economic Cooperation and Development will help the local contract research organization sector get faster access to the world's top biomedical markets for drugs developed and tested in China, said leaders at DIA's China conference May 19

You may also be interested in...



WuXi PharmaTech Disappointed With Charles River Breakup; Faces Toxicology Field Alone

SHANGHAI - WuXi PharmaTech CEO Ge Li showed his disappointment about the terminated merger with Charles River Laboratories, stressed the near-term impact will be minor, and promised to continue development of WuXi's toxicology services, during an Aug. 2 earnings call

WuXi PharmaTech Disappointed With Charles River Breakup; Faces Toxicology Field Alone

SHANGHAI - WuXi PharmaTech CEO Ge Li showed his disappointment about the terminated merger with Charles River Laboratories, stressed the near-term impact will be minor, and promised to continue development of WuXi's toxicology services, during an Aug. 2 earnings call

WuXi PharmaTech Disappointed With Charles River Breakup; Faces Toxicology Field Alone

WuXi expects to have a full service toxicology operation in China in the next five years, which would have been accelerated by a merger with Charles River. By 2015, China is expected to gain more of the global toxicology service market projected to reach $150 million to $200 million.

UsernamePublicRestriction

Register

OM013133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel